Page 138 - 南京医科大学自然版

第46卷第9期
·1408 · 南 京 医 科 大 学 学 报 2026年9月

［4］ NASSIRI F，PATIL V，YEFET L S，et al. Oncolytic DNX⁃ Gene Ther，2024，31（5）：790-801
2401 virotherapy plus pembrolizumab in recurrent glio⁃ ［15］CHEN A X，GARTRELL R D，ZHAO J F，et al. Single⁃
blastoma：a phase 1/2 trial［J］. Nat Med，2023，29（6）： cell characterization of macrophages in glioblastoma re⁃
1370-1378 veals MARCO as a mesenchymal pro⁃tumor marker［J］. Ge⁃
［5］ DUERINCK J，LESCRAUWAET L，DIRVEN I，et al. In⁃ nome Med，2021，13（1）：88
tracranial administration of anti⁃PD⁃1 and anti⁃CTLA⁃4 ［16］YEO A T，RAWAL S，DELCUZE B，et al. Single ⁃ cell
immune checkpoint ⁃ blocking monoclonal antibodies in RNA sequencing reveals evolution of immune landscape
patients with recurrent high⁃grade glioma［J］. Neuro⁃On⁃ during glioblastoma progression［J］. Nat Immunol，2022，
cology，2024，26（12）：2208-2221 23（6）：971-984
［6］ AHLUWALIA M S，REARDON D A，ABAD A P，et al. ［17］CHAN L C，LI C W，XIA W Y，et al. IL⁃6/JAK1 pathway
Phase IIa study of SurVaxM plus adjuvant temozolomide drives PD⁃L1 Y112 phosphorylation to promote cancer im⁃
for newly diagnosed glioblastoma［J］. J Clin Oncol，2023， mune evasion［J］. J Clin Invest，2019，129（8）：3324-
41（7）：1453-1465 3338
［7］ BAGLEY S J，BINDER Z A，LAMRANI L，et al. Repeat⁃ ［18］LI C W，LIM S O，XIA W Y，et al. Glycosylation and sta⁃
ed peripheral infusions of anti⁃EGFRvIII CAR T cells in bilization of programmed death ligand ⁃ 1 suppresses T ⁃
combination with pembrolizumab show no efficacy in glio⁃ cell activity［J］. Nat Commun，2016，7：12632
blastoma：a phase 1 trial［J］. Nat Cancer，2024，5（3）： ［19］GAO Y，NIHIRA N T，BU X，et al. Acetylation⁃dependent
517-531 regulation of PD⁃L1 nuclear translocation dictates the effi⁃
［8］ MCFALINE⁃FIGUEROA J R，SUN L，YOUSSEF G C，et cacy of anti ⁃ PD ⁃ 1 immunotherapy［J］. Nat Cell Biol，
al. Neoadjuvant anti ⁃ PD1 immunotherapy for surgically 2020，22（9）：1064-1075
accessible recurrent glioblastoma：clinical and molecular ［20］XU F F，SUN H M，FANG R P，et al. The modulation of
outcomes of a stage 2 single ⁃ arm expansion cohort［J］. PD⁃L1 induced by the oncogenic HBXIP for breast cancer
Nat Commun，2024，15：10757 growth［J］. Acta Pharmacol Sin，2022，43（2）：429-445
［9］ LIAU L M，ASHKAN K，BREM S，et al. Association of au⁃ ［21］ROMEO M A，GILARDINI MONTANI M S，SANTAREL⁃
tologous tumor lysate ⁃ loaded dendritic cell vaccination LI R，et al. Acetylation increases expression，interaction
with extension of survival among patients with newly diag⁃ with TRAPPC4 and surface localization of PD⁃L1［J］. Dis⁃
nosed and recurrent glioblastoma：a phase 3 prospective cov Oncol，2023，14（1）：152
externally controlled cohort trial［J］. JAMA Oncol，2023， ［22］ZHU D，XU R D，HUANG X P，et al. Deubiquitinating en⁃
9（1）：112-121 zyme OTUB1 promotes cancer cell immunosuppression
［10］OMURO A，BRANDES A A，CARPENTIER A F，et al. via preventing ER ⁃ associated degradation of immune
Radiotherapy combined with nivolumab or temozolomide checkpoint protein PD⁃L1［J］. Cell Death Differ，2021，28
for newly diagnosed glioblastoma with unmethylated （6）：1773-1789
MGMT promoter：an international randomized phase Ⅲ ［23］CHEN Y J，LI Y S，WU L. Protein S⁃palmitoylation modi⁃
trial［J］. Neuro Oncol，2023，25（1）：123-134 fication：implications in tumor and tumor immune micro⁃
［11］BROWN C E，HIBBARD J C，ALIZADEH D，et al. Lo⁃ environment［J］. Front Immunol，2024，15：1337478
coregional delivery of IL⁃13Rα2⁃targeting CAR⁃T cells in ［24］SHAHID M，KIM M，JIN P，et al. S⁃palmitoylation as a
recurrent high⁃grade glioma：a phase 1 trial［J］. Nat Med， functional regulator of proteins associated with cisplatin
2024，30（4）：1001-1012 resistance in bladder cancer［J］. Int J Biol Sci，2020，16
［12］LI X Y，ZHAO L F，LI W Z，et al. HER2⁃targeting CAR⁃T （14）：2490-2505
cells show highly efficient anti⁃tumor activity against glio⁃ ［25］GHAZI B，HARMAK Z，RGHIOUI M，et al. Decoding the
blastoma both in vitro and in vivo［J］. Genes Immun， secret of extracellular vesicles in the immune tumor micro⁃
2024，25（3）：201-208 environment of the glioblastoma：on the border of king⁃
［13］DECORDOVA S，SHASTRI A，TSOLAKI A G，et al. Mo⁃ doms［J］. Front Immunol，2024，15：1423232
lecular heterogeneity and immunosuppressive microenvi⁃ ［26］HIMES B T，PETERSON T E，DE MOOIJ T，et al. The
ronment in glioblastoma［J］. Front Immunol，2020，11： role of extracellular vesicles and PD⁃L1 in glioblastoma⁃
1402 mediated immunosuppressive monocyte induction［J］.
［14］WANG X D，GE Y Z，HOU Y T，et al. Single⁃cell atlas re⁃ Neuro Oncol，2020，22（7）：967-978
veals the immunosuppressive microenvironment and Treg ［27］ZHANG J F，BU X，WANG H Z，et al. Cyclin D⁃CDK4 ki⁃
cells landscapes in recurrent glioblastoma［J］. Cancer nase destabilizes PD⁃L1 via cullin 3⁃SPOP to control can⁃